Christina R. Lee

Publications

• Preclinical Recapitulation of Antiangiogenic Drug Clinical Efficacies Using Models of Early or Late Stage Breast Cancer Metastatis
  Breast (Edinburgh, Scotland). Aug, 2013  |   Pubmed ID: 24074794
• Differential Post-surgical Metastasis and Survival in SCID, NOD-SCID and NOD-SCID-IL-2Rγ(null) Mice with Parental and Subline Variants of Human Breast Cancer: Implications for Host Defense Mechanisms Regulating Metastasis
  PloS One. 2013  |   Pubmed ID: 23967178
• Impact of Metronomic UFT/cyclophosphamide Chemotherapy and Antiangiogenic Drug Assessed in a New Preclinical Model of Locally Advanced Orthotopic Hepatocellular Carcinoma
  Neoplasia (New York, N.Y.). Mar, 2010  |   Pubmed ID: 20234820
• Comparative Impact of Trastuzumab and Cyclophosphamide on HER-2-positive Human Breast Cancer Xenografts
  Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Oct, 2009  |   Pubmed ID: 19825954
• Glioma Tumor Stem-like Cells Promote Tumor Angiogenesis and Vasculogenesis Via Vascular Endothelial Growth Factor and Stromal-derived Factor 1
  Cancer Research. Sep, 2009  |   Pubmed ID: 19738068
• Tumor and Host-mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy
  Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Aug, 2009  |   Pubmed ID: 19671869
• Dose-dependent Increases in Circulating TGF-alpha and Other EGFR Ligands Act As Pharmacodynamic Markers for Optimal Biological Dosing of Cetuximab and Are Tumor Independent
  Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Apr, 2009  |   Pubmed ID: 19276250
• Accelerated Metastasis After Short-term Treatment with a Potent Inhibitor of Tumor Angiogenesis
  Cancer Cell. Mar, 2009  |   Pubmed ID: 19249681
• Long-term Progression and Therapeutic Response of Visceral Metastatic Disease Non-invasively Monitored in Mouse Urine Using Beta-human Choriogonadotropin Secreting Tumor Cell Lines
  Molecular Cancer Therapeutics. Oct, 2008  |   Pubmed ID: 18852148
• Vascular Endothelial Growth Factor-mediated Decrease in Plasma Soluble Vascular Endothelial Growth Factor Receptor-2 Levels As a Surrogate Biomarker for Tumor Growth
  Cancer Research. Jan, 2008  |   Pubmed ID: 18199548
• Multiple Circulating Proangiogenic Factors Induced by Sunitinib Malate Are Tumor-independent and Correlate with Antitumor Efficacy
  Proceedings of the National Academy of Sciences of the United States of America. Oct, 2007  |   Pubmed ID: 17942672
• Enhanced Natural-killer Cell and Erythropoietic Activities in VEGF-A-overexpressing Mice Delay F-MuLV-induced Erythroleukemia
  Blood. Mar, 2007  |   Pubmed ID: 17053052
• Therapy-induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors
  Science (New York, N.Y.). Sep, 2006  |   Pubmed ID: 16990548
• On the Origin and Nature of Elevated Levels of Circulating Endothelial Cells After Treatment with a Vascular Disrupting Agent
  Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Aug, 2006  |   Pubmed ID: 16921064
• Highly Efficacious Nontoxic Preclinical Treatment for Advanced Metastatic Breast Cancer Using Combination Oral UFT-cyclophosphamide Metronomic Chemotherapy
  Cancer Research. Apr, 2006  |   Pubmed ID: 16585158
• Low-dose Metronomic Combined with Intermittent Bolus-dose Cyclophosphamide is an Effective Long-term Chemotherapy Treatment Strategy
  Cancer Research. Aug, 2005  |   Pubmed ID: 16103050
• Friend Virus-induced Erythroleukemias: a Unique and Well-defined Mouse Model for the Development of Leukemia
  Anticancer Research. May-Jun, 2003  |   Pubmed ID: 12894591